Kidney Transplantation Clinical Trial
Official title:
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
The principal purpose is the study of the regulation of the expression of ephrin-B1 by immunofluorescence in kidney biopsies of patients with Chronic transplant glomerulopathy (CTG) compared to biopsies prior to the CTG, in same patients. Level of fluorescence in CTG biopsy will be the experimental reference value.
Chronic transplant glomerulopathy (CTG) is a specific lesion of kidney transplantation and a
poor prognostic factor affecting transplant survival. Diagnosis remains only microscopic and
lesions are irreversible. Recent studies prove that there is a strong correlation between
CTG and antibody mediated rejection (AMR) with a possible link with chronic aggression of
the endothelial cell. However, for unknown reason, all AMR does not lead to a CTG. Our
recent data on mice demonstrated that ephrin-B1 is expressed in the glomerular endothelial
cells and knockout mice for the gene encoding ephrin-B1 develop progressively
ultrastructural glomerular lesions close to modifications observed in CTG, as well as
proteinuria and chronic renal failure, suggesting that ephrin B1 could participate to CTG.
Moreover, in a preliminary study on human kidney transplant biopsy we observed decrease in
ephrin-B1 immunofluorescence on glomerulus when CTG, even in low grade. These data, and
ultrastructural modifications in Knock Out (KO) mice suggest that early regulation of kidney
expression of ephrin-B1 in the glomerulus may occur during the process leading to the CTG as
antibody-mediated kidney rejection (AMR).
The purpose of the study is to determinate if ephrin-B1 expression is modified in CTG.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
| Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
| Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
| Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
| Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
| Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
| Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
| Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
| Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
| Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
| Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
| Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
| Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
| Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
| Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
| Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 | |
| Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
| Completed |
NCT01672957 -
ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)
|
N/A |